Published in Clin Immunol on October 07, 2012
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol (2016) 0.94
Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis. J Autoimmun (2013) 0.89
The Th17/Treg balance and the expression of related cytokines in Uygur cervical cancer patients. Diagn Pathol (2013) 0.89
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurol Neuroimmunol Neuroinflamm (2015) 0.87
Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics (2016) 0.87
Functional defect in regulatory T cells in myasthenia gravis. Ann N Y Acad Sci (2012) 0.84
Highly heterogeneous, activated, and short-lived regulatory T cells during chronic filarial infection. Eur J Immunol (2014) 0.78
Feasibility of up-regulating CD4(+)CD25(+) Tregs by IFN-γ in myasthenia gravis patients. BMC Neurol (2015) 0.75
Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis. Ann Clin Transl Neurol (2016) 0.75
B10 Cell Frequencies and Suppressive Capacity in Myasthenia Gravis Are Associated with Disease Severity. Front Neurol (2017) 0.75
Autoreactive T Cells from Patients with Myasthenia Gravis Are Characterized by Elevated IL-17, IFN-γ, and GM-CSF and Diminished IL-10 Production. J Immunol (2016) 0.75
The potential role of cell surface complement regulators and circulating CD4+ CD25+ T-cells in the development of autoimmune myasthenia gravis. Electron Physician (2016) 0.75
The effect of IL-21 and CD4(+) CD25(++) T cells on cytokine production of CD4(+) responder T cells in patients with myasthenia gravis. Clin Exp Immunol (2017) 0.75
A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146. Front Immunol (2017) 0.75
LPS-treated bone marrow-derived dendritic cells induce immune tolerance through modulating differentiation of CD4(+) regulatory T cell subpopulations mediated by 3G11 and CD127. Immunol Res (2016) 0.75
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 17.40
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13
CD4+CD25high regulatory cells in human peripheral blood. J Immunol (2001) 11.25
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med (2006) 8.41
Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med (2001) 7.46
Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature (2007) 7.04
Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature (2007) 5.81
Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology (2000) 4.17
Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A (2009) 4.10
MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol (2006) 4.06
Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol (2003) 3.69
Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest (2006) 3.25
Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol (2007) 3.22
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol (2009) 2.86
A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest (2005) 2.71
Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity (2000) 2.71
Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest (2006) 2.58
Human regulatory T cells and their role in autoimmune disease. Immunol Rev (2006) 2.56
The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev (2006) 2.29
Persistence of naive CD45RA+ regulatory T cells in adult life. Blood (2005) 2.27
Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods (2006) 2.14
Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J Immunol (2009) 2.06
No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes (2007) 1.99
Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood (2004) 1.90
Regulation of immune responses by T cells. N Engl J Med (2006) 1.76
Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO. J Immunol (2010) 1.66
In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest (1988) 1.57
Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J Clin Invest (2008) 1.44
Undiminished regulatory T cells in the thymus of patients with myasthenia gravis. Neurology (2010) 1.43
A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell responses. J Immunol Methods (2007) 1.38
Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion. Blood (2012) 1.36
The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol (2010) 1.30
Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of FoxP3+ regulatory T cells. J Immunol (2006) 1.30
The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road. J Cell Physiol (2007) 1.29
A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann N Y Acad Sci (2003) 1.23
Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci U S A (2010) 1.23
A juxta-membrane epitope on the human acetylcholine receptor recognized by T cells in myasthenia gravis. J Clin Invest (1988) 1.19
Circulating CD4+CD25+ and CD4+CD25+ T cells in myasthenia gravis and in relation to thymectomy. Scand J Immunol (2004) 1.18
Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin Immunol (2008) 1.16
Reduced expression of FOXP3 and regulatory T-cell function in severe forms of early-onset autoimmune enteropathy. Gastroenterology (2010) 1.15
Regulatory T cells in human autoimmune diseases. Springer Semin Immunopathol (2006) 1.07
Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis. Clin Immunol (2007) 1.07
Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology (2005) 1.03
Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis. Proc Natl Acad Sci U S A (1990) 1.00
Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun (2010) 0.96
A self-reactive TCR drives the development of Foxp3+ regulatory T cells that prevent autoimmune disease. J Immunol (2011) 0.91
GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. J Neuroimmunol (2011) 0.90
The auto-antigen repertoire in myasthenia gravis. Autoimmunity (2010) 0.90
Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. J Neuroimmunol (2010) 0.88
The role of FoxP3+CD4+CD25hi Tregs in the pathogenesis of myasthenia gravis. Immunol Lett (2008) 0.86
Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients. J Immunol (2009) 0.86
T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis. Neurology (1998) 0.84
A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler (2008) 2.28
Recommendations for myasthenia gravis clinical trials. Muscle Nerve (2012) 2.28
miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet (2010) 1.97
A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A (2008) 1.39
IL-10-producing CD4+CD25+ regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J Immunol (2005) 1.34
Targeted CTLA-4 engagement induces CD4+CD25+CTLA-4high T regulatory cells with target (allo)antigen specificity. J Immunol (2004) 1.33
Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of FoxP3+ regulatory T cells. J Immunol (2006) 1.30
GM-CSF-induced CD11c+CD8a--dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis. Int Immunol (2009) 1.21
GM-CSF-induced, bone-marrow-derived dendritic cells can expand natural Tregs and induce adaptive Tregs by different mechanisms. J Leukoc Biol (2010) 1.19
Down-regulation of catalase and oxidative modification of protein kinase CK2 lead to the failure of apoptosis repressor with caspase recruitment domain to inhibit cardiomyocyte hypertrophy. J Biol Chem (2008) 1.17
Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin Immunol (2008) 1.16
Preferential costimulation by CD80 results in IL-10-dependent TGF-beta1(+) -adaptive regulatory T cell generation. J Immunol (2008) 1.11
Modulation of dendritic cells using granulocyte-macrophage colony-stimulating factor (GM-CSF) delays type 1 diabetes by enhancing CD4+CD25+ regulatory T cell function. Clin Immunol (2009) 1.11
Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid (2009) 1.07
Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve (2012) 1.06
MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells. J Biol Chem (2007) 1.05
Akt-phosphorylated mitogen-activated kinase-activating death domain protein (MADD) inhibits TRAIL-induced apoptosis by blocking Fas-associated death domain (FADD) association with death receptor 4. J Biol Chem (2010) 1.04
Enhanced engagement of CTLA-4 induces antigen-specific CD4+CD25+Foxp3+ and CD4+CD25- TGF-beta 1+ adaptive regulatory T cells. J Immunol (2007) 1.04
An advanced intercross line resolves Eae18 into two narrow quantitative trait loci syntenic to multiple sclerosis candidate loci. J Immunol (2004) 1.03
IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs. Oncogene (2004) 1.01
MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment. J Biol Chem (2009) 1.00
Regulation of apoptosis and caspase-8 expression in neuroblastoma cells by isoforms of the IG20 gene. Cancer Res (2008) 0.97
IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC. Oncogene (2004) 0.97
Targeted engagement of CTLA-4 prevents autoimmune thyroiditis. Int Immunol (2003) 0.97
Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four LMNA mutations. Hum Mutat (2011) 0.96
Identification of a new region of SARS-CoV S protein critical for viral entry. J Mol Biol (2009) 0.95
The novel role of IL-7 ligation to IL-7 receptor in myeloid cells of rheumatoid arthritis and collagen-induced arthritis. J Immunol (2013) 0.95
Type 2 deiodinase and host responses of sepsis and acute lung injury. Am J Respir Cell Mol Biol (2011) 0.94
Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS One (2012) 0.93
Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci (2003) 0.93
The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide. J Gen Virol (2009) 0.92
IG20, a MADD splice variant, increases cell susceptibility to gamma-irradiation and induces soluble mediators that suppress tumor cell growth. Cancer Res (2003) 0.92
Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors. Bioorg Med Chem Lett (2008) 0.92
Control of mitochondrial activity by miRNAs. J Cell Biochem (2012) 0.92
Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease. J Med Chem (2009) 0.92
Advanced intercross line mapping of Eae5 reveals Ncf-1 and CLDN4 as candidate genes for experimental autoimmune encephalomyelitis. J Immunol (2006) 0.91
Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection. J Virol (2010) 0.91
Broken heart syndrome in myasthenia gravis. Muscle Nerve (2011) 0.91
Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. J Interferon Cytokine Res (2011) 0.91
OX40L/Jagged1 cosignaling by GM-CSF-induced bone marrow-derived dendritic cells is required for the expansion of functional regulatory T cells. J Immunol (2013) 0.90
The gamma 1 34.5 protein of herpes simplex virus 1 is required to interfere with dendritic cell maturation during productive infection. J Virol (2009) 0.90
CD11b+GR1+ myeloid cells secrete NGF and promote trigeminal ganglion neurite growth: implications for corneal nerve regeneration. Invest Ophthalmol Vis Sci (2013) 0.90
GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. J Neuroimmunol (2011) 0.90
Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease. Muscle Nerve (2006) 0.89
Identification of human cell responses to benzene and benzene metabolites. Genomics (2007) 0.89
Absence of IL-4, and not suppression of the Th2 response, prevents development of experimental autoimmune Graves' disease. J Immunol (2003) 0.89
Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol (2011) 0.89
Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms. Virology (2009) 0.88
Dendritic cell-directed CTLA-4 engagement during pancreatic beta cell antigen presentation delays type 1 diabetes. J Immunol (2010) 0.88
Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis. J Clin Endocrinol Metab (2009) 0.88
Identification of human cell responses to hexavalent chromium. Environ Mol Mutagen (2007) 0.87
Disseminated intravascular large-cell lymphoma with initial presentation mimicking Guillain-Barré syndrome. Muscle Nerve (2010) 0.86
Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination. Cancer Chemother Pharmacol (2010) 0.86
CD80 and CD86 C domains play an important role in receptor binding and co-stimulatory properties. Int Immunol (2003) 0.86
MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. PLoS One (2013) 0.86
Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J Autoimmun (2005) 0.86
Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology (2006) 0.85
Functional defect in regulatory T cells in myasthenia gravis. Ann N Y Acad Sci (2012) 0.84
IL-1β promotes TGF-β1 and IL-2 dependent Foxp3 expression in regulatory T cells. PLoS One (2011) 0.84
Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann N Y Acad Sci (2008) 0.84
Apoptosis and autoimmune disorders. Autoimmunity (2003) 0.83
Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev Med Virol (2011) 0.83
GFPT1-myasthenia: clinical, structural, and electrophysiologic heterogeneity. Neurology (2013) 0.83
Fatigue and abnormal neuromuscular transmission in Kennedy's disease. Muscle Nerve (2003) 0.83
Transfusion of nonobese diabetic mice with allogeneic newborn blood ameliorates autoimmune diabetes and modifies the expression of selected immune response genes. J Immunol (2010) 0.81
Modulation of dendritic cell function and cytokine production to prevent thyroid autoimmunity. Autoimmunity (2003) 0.81
Acetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis? Muscle Nerve (2009) 0.80
The p53-induced Siva-1 plays a significant role in cisplatin-mediated apoptosis. J Carcinog (2009) 0.80
Activation of NF-κB in CD8+ dendritic cells Ex Vivo by the γ134.5 null mutant correlates with immunity against herpes simplex virus 1. J Virol (2011) 0.80
Resolution of a 16.8-Mb autoimmunity-regulating rat chromosome 4 region into multiple encephalomyelitis quantitative trait loci and evidence for epistasis. J Immunol (2005) 0.80
In vivo adsorption of autoantibodies in myasthenia gravis using Nanodisc-incorporated acetylcholine receptor. Exp Neurol (2010) 0.79
DC-SIGN, but not sDC-SIGN, can modulate IL-2 production from PMA- and anti-CD3-stimulated primary human CD4 T cells. Int Immunol (2005) 0.79
Characterization of a recombinant Yersinia enterocolitica lipoprotein; implications for its role in autoimmune response against thyrotropin receptor. Autoimmunity (2004) 0.79
Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J Clin Neurophysiol (2003) 0.78
Expression of the ring ligase PRAJA2 in thyroid cancer. J Clin Endocrinol Metab (2012) 0.78
Novel and recurrent EMD mutations in patients with Emery-Dreifuss muscular dystrophy, identify exon 2 as a mutation hot spot. J Hum Genet (2011) 0.78
IG20/MADD plays a critical role in glucose-induced insulin secretion. Diabetes (2013) 0.78
Diversity in the complementarity-determining region 3 (CDR3) of antibodies from mice with evolving anti-thyroid-stimulating hormone receptor antibody responses. Endocrinology (2006) 0.77
Selective destruction of mouse islet beta cells by human T lymphocytes in a newly-established humanized type 1 diabetic model. Biochem Biophys Res Commun (2010) 0.77
Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul Disord (2006) 0.77